BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 865 filers reported holding BAXTER INTL INC in Q3 2016. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $2,276,000 | -29.6% | 35,000 | -30.0% | 0.63% | -31.7% |
| Q4 2017 | $3,232,000 | +3.0% | 50,000 | 0.0% | 0.92% | +21.4% |
| Q3 2017 | $3,138,000 | +3.7% | 50,000 | 0.0% | 0.76% | +13.3% |
| Q2 2017 | $3,027,000 | -42.9% | 50,000 | -51.1% | 0.67% | -42.8% |
| Q1 2017 | $5,305,000 | -40.9% | 102,300 | -49.4% | 1.17% | -34.3% |
| Q4 2016 | $8,970,000 | -5.8% | 202,300 | +1.2% | 1.79% | +13.7% |
| Q3 2016 | $9,520,000 | +20.3% | 200,000 | +14.3% | 1.57% | +29.8% |
| Q2 2016 | $7,914,000 | +8792.1% | 175,000 | +6381.5% | 1.21% | +10900.0% |
| Q3 2015 | $89,000 | -52.9% | 2,700 | 0.0% | 0.01% | -50.0% |
| Q2 2015 | $189,000 | -25.9% | 2,700 | -27.5% | 0.02% | -18.5% |
| Q1 2015 | $255,000 | -6.6% | 3,725 | 0.0% | 0.03% | 0.0% |
| Q4 2014 | $273,000 | +2.2% | 3,725 | 0.0% | 0.03% | +17.4% |
| Q3 2014 | $267,000 | -0.7% | 3,725 | 0.0% | 0.02% | +9.5% |
| Q2 2014 | $269,000 | -50.9% | 3,725 | -50.0% | 0.02% | -48.8% |
| Q1 2014 | $548,000 | -92.7% | 7,450 | -93.1% | 0.04% | -92.3% |
| Q4 2013 | $7,473,000 | -55.8% | 107,450 | -58.3% | 0.53% | -42.7% |
| Q3 2013 | $16,912,000 | -4.2% | 257,450 | +1.0% | 0.93% | +15.5% |
| Q2 2013 | $17,660,000 | – | 254,950 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |